ArticleJournal of global health2025
Global incidence trends and projections of Alzheimer disease and other dementias: an age-period-cohort analysis 2021.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Global Microbiome: Core and Unique Signatures Across Diverse Populations.International journal of molecular sciences · 2026Pooled it
- The impact of CSF1R inhibitor-mediated microglial depletion in rodent models of Alzheimer's and Parkinson's disease: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2026Pooled it
- Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Dietary preference, biological aging, and incident dementia: a prospective cohort study.GeroScience · 2026Article
- Novel Plasma Proteins Associated With Alzheimer's Disease Risk in APOE ε4 Carriers and Non-carriers.Research square · 2026Article
- Top five Alzheimer Disease trial eligibility criteria favor men compared to women in a clinic-based cohort.The journal of prevention of Alzheimer's disease · 2026Observational
- Hormone replacement therapy and its association with LATE-NC in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The Association Between "Weekend Warrior" Physical Activity Pattern and Neuropsychological Outcomes: A Systematic Review.Behavioral sciences (Basel, Switzerland) · 2026Review
- Micro- and Nanoplastics in the Human Brain: Mechanistic Plausibility, Translational Challenges, and Links to Neurological Disease Trends.Molecular neurobiology · 2026Review
- A Global, Regional, and National Survey on Burden and Quality of Care Index of Alzheimer's Disease and Other Dementias in Adults Aged 55 and Above: The Global Burden of Disease Study 1990-2021.Neuroepidemiology · 2026Article
- Emerging neuroprotective mechanisms and therapeutic potential of natural polysaccharides in Alzheimer's disease.Frontiers in aging neuroscience · 2026Review
- Dynamic trends, spatial clustering, and multi-model projections of the global burden of Alzheimer's disease and other dementias: an analysis of GBD 1990-2021 data to 2050.Frontiers in aging neuroscience · 2026Article
- Trends in PCOS Incidence, Prevalence, and DALYs Across Five BRICS Nations, 1990-2050: A Decomposition, Age-Period-Cohort, and Bayesian Forecasting Analysis Based on GBD 2021.International journal of women's health · 2026Article
- Application of Photostimulation Therapy in Cognitive Function of Alzheimer's Disease Patients: A Scoping Review.Clinical interventions in aging · 2026Article
- Severe Neurological Disorders in the Greenlandic Population: A Nationwide Register-Based Study.Brain and behavior · 2025Article
- Glycosphingolipids in Dementia: Insights from Mass Spectrometry and Systems Biology Approaches.Biomedicines · 2025Review
- Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures.Cells · 2025Review
- AQP4 Drives Gliotic Changes in an APPPS1 Mouse Model of Alzheimer's Disease.Current health sciences journalArticle
- Exploring precision medicine by utilizing individual genetic information for the management of Alzheimer's disease.PharmacogenomicsReview
- Association between circulating biomarkers of one-carbon metabolism and glymphatic system function in cognitive decline of Alzheimer's disease.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer disease (AD) is a growing global health issue, with incidence varying by gender, age, and region. Understanding these trends is essential for developing effective prevention strategies as the population ages. Unlike previous Global Burden of Disease (GBD) studies that primarily focussed on prevalence and mortality, we offer a novel perspective by examining historical incidence trends and projecting future patterns of AD and other dementias using advanced analytical approaches. Methods: We used data from 204 countries and 21 global regions from the GBD 2021 database. We applied the age-period-cohort (APC) model to analyse historical incidence trends, and the Bayesian APC (BAPC) model to forecast future incidence from 2022-36. These models help reveal changes related to age, period, and birth cohort and enable forecasting of future trends - analytical perspectives not provided in the original GBD data sets or their supplementary documents. Results: Between 1992-2021, global AD cases increased from 4.078 million to 9.837 million, while the global age-standardised incidence rate (ASIR) remained relatively stable, rising slightly from 117.7 to 119.8 per 100 000. ASIR increased significantly in high-middle and middle-sociodemographic index regions, but declined in the low-sociodemographic index regions. Women consistently exhibited higher incidence rates than men across all regions. Projections indicate that 2036 global AD cases will reach 19.117 million, with an ASIR of 418.92 per 100 000. Conclusions: While global ASIR has remained stable, the number of AD cases continues to rise due to population ageing, particularly in middle- and high-income regions. Low-income regions face additional challenges due to limited health care resources. Gender disparities and unequal access to health care contribute to the variations in disease burden. These findings emphasise the need to prioritise early diagnosis and implement targeted interventions to reduce future disease burdens and address global health care inequalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.